Reading Time: 2 minutes
The stock of Moderna is currently in a multi-year downtrend and could be forming a bottom, after the company raised its forecast for the fiscal year 2025 at the J.P. Morgan Healthcare Conference on January 12th. I believe growth this year will come from the oncology pipeline, which is on the verge of critical breakthroughs. In particular, the personalized cancer vaccine V940 (Intismeran) in combination with Keytruda could revolutionize cancer treatment. The Phase III results expected this year and the 5-year data on melanoma are massive catalysts....
Read this article now with a free account.
Your benefits:
- Every month, you can read 5 articles from the premium section for free.
- Monthly 2 trial issues of the Trader newspaper for free.
- Create a personal watchlist with an overview of news about your stock.
